Reimbursement Review Reports

The latest CADTH Reimbursement Review reports are posted to this page. CADTH reimbursement reviews are comprehensive assessments of the clinical effectiveness and cost-effectiveness, as well as patient and clinician perspectives, of a drug or drug class. The assessments inform non-binding recommendations that help guide the reimbursement decisions of Canada's federal, provincial, and territorial governments, with the exception of Quebec. Implementation advice and funding algorithms are provided where applicable.

Brand Name Sort ascending Generic Name Therapeutic Area Recommendation Type Project Status Date Submission Received Date Recommendation Issued
Crysvita burosumab Treatment of X-Linked Hypophosphatemia Active
Crysvita burosumab Treatment of X-Linked Hypophosphatemia Reimburse with clinical criteria and/or conditions Complete
Cresemba isavuconazole Treatment of invasive aspergillosis and mucormycosis Reimburse with clinical criteria and/or conditions Complete
Cotellic Cobimetinib Metastatic melanoma Reimburse with clinical criteria and/or conditions Complete
Cosentyx secukinumab Hidradenitis suppurativa Suspended
Cosentyx Secukinumab Plaque psoriasis List with criteria/condition Complete
Cosentyx Secukinumab ankylosing spondylitis Reimburse with clinical criteria and/or conditions Complete
Cosentyx Secukinumab Arthritis, psoriatic Reimburse with clinical criteria and/or conditions Complete
Corzyna ranolazine Stable angina pectoris, adults Do not reimburse Complete
Cortiment Budesonide Ulcerative Colitis Do not reimburse Complete